cerca CERCA
Lunedì 23 Maggio 2022
Aggiornato: 19:58
Temi caldi

Comunicato stampa

Life Sciences Companies Speed Clinical Trial Management with Veeva Vault CTMS

13 maggio 2021 | 13.04
LETTURA: 3 minuti

More than 100 organizations use Vault CTMS to unify data and processes for faster, more efficient trials

BARCELONA, Spain, May 13, 2021 /PRNewswire/ -- As the need for greater efficiency in studies grows, more than 100 companies are streamlining trial management and monitoring with Veeva Vault CTMS. Fast-growing companies and global organizations are modernizing their clinical systems landscape and investing in unified applications from Veeva Systems (NYSE: VEEV) to increase visibility across trials and accelerate study execution.

"We needed a scalable clinical system that can grow with us while supporting multiple operating models and complex study designs," said Charles Johnson, director eClinical operations at CSL Behring. "Veeva Vault CTMS delivers the flexibility to meet our unique business requirements and seamlessly share information with Veeva Vault eTMF, significantly reducing data entry and streamlining document filing."

Usability issues with legacy systems have driven the industry to rely on manual and paper-based processes that slow down studies. With Vault CTMS, customers are simplifying costly and time-consuming processes like site monitoring by enabling CRAs to auto-generate trip reports and file them seamlessly within Vault eTMF. The increased productivity allows users to move faster while ensuring compliance.

"Our clinical research associates used to spend more than 160 hours per study preparing trip reports in our homegrown CTMS application," said Hunter Walker, CTO at Atlantic Research Group. "Veeva Vault CTMS significantly decreased monitoring time, lowered trial costs, and simplified execution, enabling us to deliver greater efficiencies to our clients."

"There is incredible momentum in the adoption of Veeva Vault CTMS because of its ability to scale with growing companies and improve trial oversight for sponsors and CROs," said Henry Galio, senior director, Veeva Vault CTMS. "We are laser-focused on helping customers of all sizes speed execution and lower costs in clinical research."

Vault CTMS is part of the Veeva Vault Clinical Operations Suite, enabling companies to share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.

Learn more about Vault CTMS at the upcoming Veeva R&D and Quality Summit Connect Europe, 20 May 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.  

Additional InformationFor more on Veeva Vault CTMS, visit: veeva.com/CTMSConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systemsFollow @veeva_eu on Twitter: twitter.com/veeva_eu 

About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Forward-looking StatementsThis release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2021. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time. 


Deivis MercadoVeeva Systems925-226-8821deivis.mercado@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg


Riproduzione riservata
© Copyright Adnkronos
Vedi anche
ora in
Prima pagina
in Evidenza